Last reviewed · How we verify
Fluarix-AS25
Fluarix-AS25 is an inactivated influenza vaccine.
Fluarix-AS25 is an inactivated influenza vaccine. Used for Protection against influenza disease caused by the AS25 strain of the influenza virus.
At a glance
| Generic name | Fluarix-AS25 |
|---|---|
| Also known as | Fluarix vaccine adjuvanted with AS25 |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against the influenza virus, providing protection against infection.
Approved indications
- Protection against influenza disease caused by the AS25 strain of the influenza virus
Common side effects
- Pain, redness, swelling, or itching at the injection site
Key clinical trials
- Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population (PHASE2)
- Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |